CEN Biotech Inc
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial, medical, and food products; and to provide digital marketing and web design related services. The company was incorporated in 2013 and is based in Windsor, Canada.
CEN Biotech Inc (CENBF) - Net Assets
Latest net assets as of September 2023: $-2.53 Million USD
Based on the latest financial reports, CEN Biotech Inc (CENBF) has net assets worth $-2.53 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.09 Million) and total liabilities ($10.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.53 Million |
| % of Total Assets | -31.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CEN Biotech Inc - Net Assets Trend (2014–2022)
This chart illustrates how CEN Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CEN Biotech Inc (2014–2022)
The table below shows the annual net assets of CEN Biotech Inc from 2014 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-2.29 Million | -38.19% |
| 2021-12-31 | $-1.66 Million | +83.40% |
| 2020-12-31 | $-9.99 Million | +60.87% |
| 2019-12-31 | $-25.54 Million | -20.10% |
| 2018-12-31 | $-21.26 Million | -11.82% |
| 2017-12-31 | $-19.01 Million | -42.12% |
| 2016-12-31 | $-13.38 Million | -130.38% |
| 2015-12-31 | $-5.81 Million | -70.76% |
| 2014-12-31 | $-3.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CEN Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4724121200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-35.76K | % |
| Other Components | $45.22 Million | % |
| Total Equity | $-2.29 Million | 100.00% |
CEN Biotech Inc Competitors by Market Cap
The table below lists competitors of CEN Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
$2.59K |
|
New Providence Acquisition Corp. III Warrants
NASDAQ:NPACW
|
$2.59K |
|
Amigo Holdings PLC
LSE:AMGO
|
$2.59K |
|
Prestwick Capital Corporation Limited
V:PWIK-P
|
$2.59K |
|
Works co uk PLC
LSE:WRKS
|
$2.59K |
|
Abadi Lestari Indonesia Tbk
JK:RLCO
|
$2.58K |
|
Zefiro Methane Corp.
NEO:ZEFI
|
$2.58K |
|
Pricer AB
STU:PRRB
|
$2.58K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CEN Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -1,658,131 to -2,291,354, a change of -633,223.
- Net loss of 1,515,000 reduced equity.
- Other comprehensive income decreased equity by 1,835.
- Other factors increased equity by 883,612.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.51 Million | -66.12% |
| Other Comprehensive Income | $-1.83K | -0.08% |
| Other Changes | $883.61K | +38.56% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CEN Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.03 | $0.00 | x |
| 2014-12-31 | $-0.49 | $0.00 | x |
| 2015-12-31 | $-0.83 | $0.00 | x |
| 2016-12-31 | $-1.63 | $0.00 | x |
| 2017-12-31 | $-2.26 | $0.00 | x |
| 2018-12-31 | $-0.84 | $0.00 | x |
| 2019-12-31 | $-0.97 | $0.00 | x |
| 2020-12-31 | $-0.31 | $0.00 | x |
| 2021-12-31 | $-0.04 | $0.00 | x |
| 2022-12-31 | $-0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CEN Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -153.48%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-547.23K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.82 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.83 Million |
| 2016 | 0.00% | -326669.54% | 0.00x | 0.00x | $-6.24 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.18 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.40 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $15.25 Million |
| 2021 | 0.00% | -3015.63% | 0.07x | 0.00x | $-18.74 Million |
| 2022 | 0.00% | -153.48% | 0.13x | 0.00x | $-1.29 Million |
Industry Comparison
This section compares CEN Biotech Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CEN Biotech Inc (CENBF) | $-2.53 Million | 0.00% | N/A | $2.59K |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |